Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06402201 · ClinicalTrials.gov registry record · Phase 1
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
A Phase 1 study of Select Advanced Solid Tumors, sponsored by CDR-Life.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 18
- Study locations
NCT06402201: Recruiting Phase 1 study of Select Advanced Solid Tumors, sponsored by CDR-Life.
NCT06402201 is a Phase 1 study of Select Advanced Solid Tumors that is actively recruiting participants, run by CDR-Life. The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). The trial reports 18 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06402201, a Phase 1 study of Select Advanced Solid Tumors, is actively recruiting participants, sponsored by CDR-Life.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 18
- Study locations
Study Summary
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A\*02:01 tissue marker and whose cancer is positive for MAGE-A4.
Primary Outcome
per Protocol
Conditions Studied
Interventions
- BIOLOGICAL CDR404
Study Locations (18)
Other
- Universitair Ziekenhuis Antwerpen - Antwerp
- Institut Jules Bordet - Brussels
- Cliniques Universitaires Saint-Luc, UCL Ouvain - Brussels
- Universitair Ziekenhuis Gent - Ghent
- Rigshospitalet - Copenhagen
- Istituto Clinico Humanitas - Milan
- Isituto Europeo di Oncologia (IEO) - Milan
- Hospital Universitari Vall d'Hebron - Barcelona
- Institut Catala d'Oncologia, L'Hospitalet de Llobregat (ICO) - Barcelona
- Hospital 12 de Octubre - Madrid
- START Madrid - Madrid
- Hospital Universitari i Politecnic La Fe - Valencia
- Instituto de Investigacion Sanitaria (INCLIVA) - Valencia
Florida
- University of Miami - Miami
Michigan
- University of Michigan - Ann Arbor
Oregon
- Providence Cancer Institute - Portland
Pennsylvania
- Pennsylvania Hospital - Philadelphia
London
- Royal Marsden Hospital - Sutton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2024-05-24 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT06402201 shows while recruiting
NCT06402201 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Select Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which CDR404 is the first listed.
NCT06402201 lists 18 locations in 6 states (Other, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT06402201 about?
NCT06402201 is a clinical study titled "First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors". CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and prelimina...
What is the current status of trial NCT06402201?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2024-05-24. Estimated completion is 2027-12-31.
What conditions does trial NCT06402201 study?
This clinical trial studies the following conditions: Select Advanced Solid Tumors.
What interventions are being tested in trial NCT06402201?
The interventions under investigation include: CDR404 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06402201?
This trial is sponsored by CDR-Life, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06402201 being conducted?
This trial has 18 study locations across Florida, Michigan, Oregon, Pennsylvania, London. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Select Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06402201's enrollment target sits among peer trials
42 1106th of 2000 higher than 876 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI